ArticleMedicine2026
In vitro fertilization increases the risk of placenta accreta spectrum in second-trimester pregnancy loss: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of placenta accreta spectrum (PAS) associated with in vitro fertilization and embryo transfer (IVF-ET) in the context of mid-trimester pregnancy loss remains unclear. This study aimed to investigate the impact of IVF-ET on the incidence of PAS and identify the risk factors among women undergoing pregnancy loss following fetal demise or inevitable miscarriage during the second trimester. In our retrospective cohort study, we analyzed women who experienced second-trimester fetal loss due to fetal demise or inevitable miscarriage at the Sixth Affiliated Hospital of Sun Yat-sen University between January 2013 and October 2023. The participants were categorized into IVF-ET (n = 93) and non-IVF-ET (n = 134) groups. The primary outcome was the incidence of PAS, which was diagnosed clinically or pathologically. Secondary outcomes included morbid PAS, postpartum hemorrhage, and other complications. Our results indicated that the IVF-ET group had a significantly greater risk of experiencing PAS (39.8% vs 17.9%, P < .001) and morbid PAS (17.2% vs 3.7%, P < .001) compared to the non-IVF-ET group. The median postpartum blood loss was greater (230.0 [120.0-600.0] mL vs 120.0 [70.0-200.0] mL, P < .001), and the rates of postpartum hemorrhage (30.1% vs 12.7%, P = .001) and retained products of conception persisting >4 weeks (38.7% vs 19.4%, P < .001) were also greater in the IVF-ET group. Multivariate analysis revealed IVF-ET (adjusted odds ratio [aOR] = 3.13; P = .002), a hysteroscopic history (aOR = 3.58; P = .02), and uterine abnormalities (aOR = 3.74; P = .02) as independent risk factors for PAS. In the IVF-ET group, compared with fresh embryo transfer, cryopreserved embryo transfer (aOR = 3.52; P = .01) was associated with a markedly higher risk of PAS (50.9% vs 22.2%, P = .006) and remained an independent risk factor after adjustment (aOR = 3.52; P = .01). Among women with mid-trimester pregnancy loss, those who underwent IVF-ET, especially cryopreserved embryo transfer, had a high risk of PAS, leading to increased hemorrhagic morbidity and complications. These findings highlight the need for enhanced preoperative assessment, vigilant management, and strategies to preserve fertility in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.